

Published in final edited form as:

Atherosclerosis. 2009 March ; 203(1): 67–74. doi:10.1016/j.atherosclerosis.2008.05.060.

## C-reactive protein stimulates superoxide anion release and tissue factor activity *in vivo*

Sridevi Devaraj<sup>a</sup>, Mohan R. Dasu<sup>a</sup>, Uma Singh<sup>a</sup>, L. Vijaya Mohan Rao<sup>b</sup>, and Ishwarlal Jialal<sup>a,\*</sup>

<sup>a</sup> The Laboratory for Atherosclerosis and Metabolic Research, Department of Medical Pathology and Laboratory Medicine, UC Davis Medical Center, Sacramento, CA 95817, United States

<sup>b</sup> The University of Texas Health Center at Tyler, TX, United States

### Abstract

C-reactive protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and recent *in vitro* studies suggest that it may promote atherogenesis. CRP promotes oxidative stress *in vitro* and induces tissue factor (TF) release. However, there is a paucity of data examining the effects of CRP on oxidative stress and tissue factor procoagulant activity (PCA) *in vivo*. Thus, we tested the effects of CRP administration on superoxide anion release and tissue factor activity and examined mechanistic pathways using a rat sterile air pouch model. Intraperitoneal administration of CRP (20 mg/kg body weight) compared to human serum albumin (HuSA) increased superoxide anion release and tissue factor activity from peritoneal macrophages *in vivo* ( $p < 0.01$ ). This was confirmed using intrapouch administration of CRP (25  $\mu\text{g}/\text{mL}$ ) compared to HuSA. Pretreatment with reactive oxygen species (ROS) scavengers or protein kinase C (PKC) inhibitor significantly abrogated CRP-induced superoxide anion release and tissue factor activity. Pretreatment with extracellular signal-regulated kinase (ERK) and Jun N-terminal kinase (JNK) inhibitors, but not p38 mitogen-activated protein kinase (p38MAPK) significantly decreased CRP-induced superoxide anion release from macrophages *in vivo*. CRP-induced tissue factor activity *in vivo* was abrogated by pretreatment with inhibitors to p38MAPK, JNK and NF $\kappa$ b (nuclear factor- $\kappa$ b), but not ERK. Antibodies to Fc gamma receptors, CD32 and CD64 resulted in significant reduction in CRP-induced superoxide and tissue factor activity *in vivo*. Thus, CRP appears to induce oxidative stress *in vivo* by stimulating NADPH oxidase via PKC, ERK and JNK phosphorylation, and induces tissue factor PCA *in vivo* via upregulation of PKC, p38MAPK, JNK, ROS and NF $\kappa$ b. CRP-induced ROS appears to precede tissue factor release. These effects are abrogated by blocking Fc gamma receptors, CD32 and CD64. This *in vivo* demonstration provides further evidence for a role for CRP in atherothrombosis.

### Keywords

Macrophages; Oxidative stress; Rat; Mechanistic insights; Tissue factor; Procoagulant

## 1. Introduction

Increasing evidence supports the involvement of inflammation and oxidative stress in the pathogenesis of atherosclerosis [1,2]. C-reactive protein (CRP), the prototypic marker of inflammation, has been shown in numerous studies to predict cardiovascular events. In addition

\*Corresponding author at: The Laboratory for Atherosclerosis and Metabolic Research, Department of Medical Pathology and Laboratory Medicine, UC Davis Medical Center, 4635 2nd Avenue, Room # 3000, Research Building 1, Sacramento, CA 95817, United States., Tel.: +1 916 734 6592; fax: +916 734 6593., E-mail address: ishwarlal.jialal@ucdmc.ucdavis.edu (I. Jialal).

to being a risk marker, CRP by enhancing inflammation, oxidative stress and procoagulant activity (PCA), appears to mediate atherothrombosis [3].

CRP induces oxidative stress *in vitro*, i.e., superoxide production in various cells including endothelial cells, smooth muscle cells and monocyte–macrophages, which are involved in the process of atherosclerosis [4–8]. Furthermore, *in situ* hybridization revealed the presence of CRP mRNA in coronary vasculature and CRP was frequently colocalized with p22phox, an essential component of NADPH oxidase, which is an important source of reactive oxygen species (ROS) in vasculature [9]. Kobayashi et al. [9] showed that the incubation of cultured coronary artery smooth muscle cells with CRP resulted in enhanced p22phox protein expression and in the generation of intracellular ROS. We have previously shown, *in vitro* in human aortic endothelial cells (HAEC), that CRP stimulates superoxide anion release and results in increased nitration of prostaglandin synthase, resulting in decreased prostacyclin release [4]. We have recently demonstrated *in vivo* that CRP promotes oxidized LDL (Ox-LDL) uptake and matrix metalloproteinase-9 (MMP-9) release from rat macrophages [10]. Thus, in this study, we wished to examine the effect of CRP *in vivo* on superoxide anion release and examine plausible mechanisms.

Several studies indicate that CRP appears to promote a procoagulant diathesis as reviewed previously [3]. CRP upregulates tissue factor (TF) activity in monocytes and cultured vascular smooth muscle cells, CRP upregulates PAI-1 and decreases tPA, eNOS and prostacyclin in HAEC [3,5,11,12]. Furthermore, mice carrying the human CRP (HCRP) transgene exhibit accelerated thrombosis after vascular injury [13]. However, mice do not appear to be an appropriate model to test CRP's effects *in vivo* and the data appear to be equivocal [3].

As reviewed previously [3], the rat appears to be the preferred model to test CRP's effects due to the following reasons: in mice the main acute-phase reactant is serum amyloid P (SAP) component and serum amyloid A, not CRP. Human CRP is anti-inflammatory in mice and rat CRP shares 79% identity with human CRP. Griselli et al. [14] showed that parenteral injection of human CRP in experimental acute myocardial infarction produced by coronary artery ligation reproducibly enhanced infarct size by ~40%. Gill et al. [15] also showed that adult rats subjected to middle cerebral artery occlusion and then treated with human CRP similarly developed significantly larger cerebral infarcts compared with control animals receiving human serum albumin (HuSA). Human CRP activates complement in rats. Human CRP has been shown to be pro-inflammatory in the rat and increases inducible nitric oxide synthase expression in cytokine-stimulated rat cardiac myocytes, as well as inducible nitric oxide synthase in rat macrophages, and stimulates nuclear factor- $\kappa$ b (NF $\kappa$ b) in rat vascular smooth muscle cells [3,12,16,17]. Also, the Pepys group [18] has shown that a small molecule inhibitor (bis-phosphatidylcholine) to CRP prevents the increase in infarct size following coronary ligation. We recently showed that CRP induced Ox-LDL uptake and MMP-9 from rat macrophages *in vivo* using the sterile pouch model [10]. Thus, we chose this model to test CRP's effects on tissue factor procoagulant activity *in vivo*.

In this report, we demonstrate for the first time that CRP induces superoxide anion release and tissue factor activity in rat macrophages *in vivo*.

## 2. Materials and methods

HCRP was purified from human ascitic/pleural fluids as described by Du Clos et al. [19] and had endotoxin levels <12.5 pg/mL as described previously [5,10]. Recently, we have shown that our in-house purified, dialyzed CRP mediates its inflammatory effects in TLR4 knocked down cells providing further cogent data that CRP-mediated effects are not due to endotoxin contamination [20].

Ficoll, SB203580 (a p38 mitogen-activated protein kinase (MAPK) inhibitor), PD 098059 (an extracellular signal-regulated kinase (ERK) 1/2 ERK inhibitor), caffeic acid phenethyl ester (CAPE) (an NF $\kappa$ b inhibitor), SP600125 (a Jun N-terminal kinase (JNK) inhibitor), apocynin, *N*-acetyl cysteine (NAC), diphenylene iodonium (DPI) and HuSA were from Sigma Chemical Company.

### 2.1. Animal treatment

Male hooded Wistar rats (weighing 125–150 g) were obtained from Charles River Lab. Animals were housed in a controlled environment at an ambient temperature of  $21 \pm 2$  °C on a 12 h light:dark cycle. Food and water were provided *ad libitum*. The rats were acclimatized to animal housing conditions for 1 week. The protocol was approved by the Animal Committee of University of California at Davis. Two different routes of administration for HCRP or HuSA were used *in vivo*—(i) intraperitoneal model: CRP administered intraperitoneally and (ii) sterile pouch model: CRP administered in sterile air pouch. The pouch model was used mainly for mechanistic studies since the purification of CRP is time-consuming, laborious and very expensive and the sterile pouch model requires smaller amounts of protein [10].

### 2.2. Intraperitoneal model

HCRP/HuSA (20 mg/kg body weight for 3 days,  $n = 5$  in each group) was injected in the peritoneal cavity of the rats. The rats were sacrificed on the 4th day by overdose of pentobarbital and peritoneal macrophages were isolated as described previously [10] and used for further analysis.

### 2.3. Sterile air pouch model

The sterile air pouches were formed on the dorsal surface of the rats as described previously [10,21]. The sterile air pouch model has been very recently published and validated by our group to examine pro-inflammatory effects of CRP in rat *in vivo* [10]. Briefly, under mild isoflurane sedation, the backs of Wistar rats were shaved and cleaned with alcohol swabs. At approximately 1.5 in. from mid neck 20 mL of sterile air attached to 23-G needle syringe was subcutaneously injected. HCRP/HuSA (25  $\mu$ g/mL intrapouch) was directly injected into the pouch cavities of lightly restrained (hand-held) conscious animals on the 3rd day after the formation of pouch. For the mechanistic studies, the inhibitors/antibodies were injected into the pouch 2–4 h before injection of HCRP. The rats were euthanized on the following day by overdose of pentobarbital. The washouts of the pouch were made by deflating the pouch, irrigating with normal saline and its aspiration. The cells were pelleted by centrifugation and supernatants were used as pouch exudates.

### 2.4. Superoxide anion release

Superoxide anion release from peritoneal and pouch macrophages was assessed by acetylated ferricytochrome C reduction as described previously [4]. Also, superoxide release was assessed by dihydroethidium (DHE) fluorescence [4,5]. The results were standardized to milligram protein content.

### 2.5. Tissue factor activity

Peritoneal/pouch macrophages were stored in octylpyranoside to measure tissue factor activity by the method of Pendurthi and Rao [22]. Lysates in RIPA buffer were placed in a 96-well plate and 10 nM of FVIIa was added, after 5 min, factor X (175 nM) was added and incubated for 15 min at 37 °C. To measure Xa generation, 25  $\mu$ L of S-2765 was added to each well and absorbance measured for 2 min at 405 nm. TF activity was calculated using relipidated TF as standard in the assay and standardized to milligram protein content.

## 2.6. Mechanistic studies for CRP-induced superoxide anion release and tissue factor activity

These experiments were performed using the pouch model. The rats were divided into different groups ( $n = 4$  rats per group): (1) HuSA; (2) HCRP; (3) SB203580 (1 mg/kg bw) + HCRP; (4) PD 098059 (0.5 mg/kg bw) + HCRP; (5) SP600125 (1 mg/kg bw) + HCRP; (6) CAPE (0.2 mg/kg bw) + HCRP; (7) apocynin (100  $\mu\text{g}/\text{mL}$ ) + HCRP; (8) calphostin C (10  $\mu\text{M}$ ) + HCRP; (9) diphenylene iodonium (DPI, 10  $\mu\text{M}$ ) + HCRP and (10) NAC (10  $\mu\text{g}/\text{mL}$ ) + HCRP. On the 3rd day after the formation of the pouches, various inhibitors were injected in the pouches at specific concentrations as described in literature for *in vivo* use [10]. HuSA or HCRP was injected 2 h after the injection of inhibitors followed by euthanization of rats after 12–16 h. The pouch exudates and cells were obtained for measurement of super-oxide release and tissue factor activity.

## 2.7. Involvement of the receptor type in CRP-mediated superoxide anion release and tissue factor activity

The pouch model was used to explore the specific receptor type involved. Blocking antibodies (10  $\mu\text{g}/\text{mL}$  intrapouch) to CD32, CD64, CD16 or irrelevant IgG either alone or their combinations (CD32 + CD64) were injected in the rats (3 per group) pouches 2 h prior to HCRP injection. Rats were euthanized 12–16 h later as described [10] and pouch macrophages and exudates were collected for measurement of superoxide release and tissue factor activity.

## 2.8. Statistical analysis

All experiments were performed at least three times in duplicate. The comparisons between group means were analyzed using ANOVA. The experimental results are presented as the mean  $\pm$  S.D. Paired *t*-tests were used to compute differences in the variables, and the level of significance was set at  $p < 0.05$ .

## 3. Results

Intraperitoneal administration of human CRP (20 mg/kg) compared to HuSA stimulated superoxide anion release (Fig. 1a) and tissue factor activity from peritoneal macrophages *in vivo* ( $p < 0.01$ ) (Fig. 1b). This was also confirmed using intrapouch administration of CRP (25  $\mu\text{g}/\text{mL}$ ) compared to HuSA (Fig. 2a and b).

### 3.1. Mechanistic insights for CRP-mediated superoxide release and tissue factor in vivo

Since protein kinase C (PKC) drives superoxide release from monocytes via activation of NADPH oxidase [23], we examined the effect of PKC and NADPH oxidase inhibitors on CRP-induced superoxide anion release as well as tissue factor activity *in vivo*.

Pretreatment with the PKC inhibitor, calphostin C, and the NADPH oxidase inhibitor, apocynin, significantly abrogated CRP-induced superoxide anion release (Fig. 2a). To examine if ROS and PKC upregulation affect CRP-induced tissue factor activity *in vivo*, we examined three ROS scavengers, NAC, DPI, apocynin (NADPH oxidase inhibitor) and calphostin C (PKC inhibitor). Inhibitors of PKC and ROS significantly abrogated CRP-induced tissue factor activity *in vivo* (Fig. 2b).

Furthermore, we have shown previously that CRP-induced MMP-9 in rat macrophages *in vivo* is abrogated by MAPK inhibitors [10]. In this study, pretreatment with ERK and JNK inhibitors and NF $\kappa$ b inhibitor, but not p38MAPK significantly decreased CRP-induced superoxide anion release from pouch macrophages *in vivo* (Fig. 3a). With regards to CRP-induced tissue factor activity *in vivo*, this was abrogated by pretreatment with inhibitors to p38MAPK, JNK and NF $\kappa$ b, but not by the ERK inhibitor (Fig. 3b).

Previously, CRP has been shown to mediate its biological effects in endothelial cells and monocyte-macrophages via CD32 and CD64 [3–5,10–12,24–28]. Thus, we examined the effects of antibodies to CD16, CD32 and CD64 on CRP-induced superoxide anion release and tissue factor activity. We demonstrate that antibodies to Fc gamma receptors, CD32 and CD64, but not CD16 resulted in significant reduction in CRP-induced superoxide and tissue factor activity *in vivo* (Fig. 4a and b).

#### 4. Discussion

In this paper, we demonstrate that CRP appears to induce oxidative stress *in vivo* via upregulation of PKC, NADPH oxidase, ERK and JNK phosphorylation, while CRP also induces tissue factor procoagulant activity *in vivo* via upregulation of PKC, NADPH oxidase, ROS, p38MAPK, JNK and NF $\kappa$ b. These effects are abrogated by blocking Fc gamma receptors, CD32 and CD64.

In the present study, CRP induced the release of super-oxide anion and tissue factor from pouch macrophages at a concentration of 25  $\mu$ g/mL. Importantly, Ridker et al. [29] have shown that CRP levels >20  $\mu$ g/mL predict future cardiovascular events. Also, several investigators have reported that CRP concentrations in the setting of acute coronary syndromes range up to 50  $\mu$ g/mL [30,31]. Thus, the levels of CRP shown to induce superoxide/tissue factor release *in vivo* in this study can clearly be attained in patients.

With regards to superoxide anion release, several investigators have demonstrated that CRP induces superoxide anion release from cells *in vitro*. Prasad [32] have shown that in neutrophils, CRP significantly and dose-dependently induces superoxide anion release *in vitro*, however, no mechanistic studies were undertaken. Exposure of rat mesangial cells to CRP for 60 min led to a dose-dependent increase in superoxide anion release that was nearly threefold greater than that in the control conditions ( $p < 0.0001$ ) [33]. They also showed that co-incubation with DPI (10  $\mu$ M) prevented the increase in superoxide production by rat mesangial cells induced by CRP (100  $\mu$ g/mL). While they used high concentrations of CRP in their *in vitro* studies, we show that at lower concentrations of CRP (25  $\mu$ g/mL) *in vivo*, CRP induces superoxide anion release and that this is attenuated by inhibition of PKC and apocynin, a specific inhibitor of NADPH oxidase. Previously, we showed that CRP promotes superoxide anion release from HAEC and induces eNOS uncoupling and this is inhibited by siRNA to p22phox and p47phox [5]. Also, Kobayashi et al. [9] have shown that CRP in lesions colocalizes with p22phox, another component of NADPH oxidase, and this is in support of our findings. Furthermore, Qamirani et al. [7] showed that in porcine coronary arterioles treated with CRP (7  $\mu$ g/mL; 1 h), using DHE staining that CRP produced SB203850- and TEMPOL-sensitive superoxide production in the arteriolar endothelium. CRP treatment of coronary arterioles significantly increased NAD(P)H oxidase activity and this was mediated via p38MAPK activation. In this report, in rat pouch macrophages, we demonstrate that CRP's *in vivo* effects on superoxide anion release were inhibited via inhibition of ERK, but not p38MAPK.

With regards to tissue factor release, one of the first groups that demonstrated that human CRP-induced tissue factor release *in vitro* was Cermak et al. [34]. Cermak showed that CRP (10–100  $\mu$ g/mL) induced a 75-fold increase in TF PCA of human peripheral blood mononuclear cells, with a parallel increase in TF antigen levels. Later studies have shown that peripheral blood mononuclear cells also respond in a similar fashion to CRP [35]. Previously, CRP has been shown to induce procoagulant activity as observed by increased endothelial PAI-1 and decreased tPA [3]. Cirillo et al. [36] demonstrated that incubation of endothelial cells and smooth muscle cells with CRP resulted in a dose-dependent activation of cell proliferation, which was mediated by activation of the ERK 1/2 pathway. In addition, CRP also induced TF expression in both cell types in a dose-dependent fashion, exerting its effect at the



transcriptional level, as demonstrated by semiquantitative and by real-time PCR. Activation of the transcription factor, NF $\kappa$ b, by CRP was demonstrated by EMSA and they also demonstrated suppression of TF expression by the NF $\kappa$ b inhibitor, pyrrolidine-dithiocarbamate ammonium [12,36]. In rat pouch macrophages, *in vivo*, we show for the first time that CRP-induced TF is inhibited by inhibitors to p38MAPK and JNK, but not ERK inhibitor. Furthermore, we have previously shown *in vivo* that CRP augments NF $\kappa$ b activity in rat pouch macrophages. In this paper, in support of the work of Cirillo et al. [36], we show that inhibition of NF $\kappa$ b activity with CAPE, resulted in significant inhibition of CRP-induced TF activity *in vivo*. Furthermore, using three scavengers of ROS, we demonstrate a link between CRP-induced superoxide release and TF activity, since all three inhibitors significantly abrogate CRP-induced TF activity. Mechanisms by which increased oxidative stress results in increased CRP-induced TF activity *in vivo* will be explored in future studies. Also, we have previously shown that CRP upregulates pro-inflammatory cytokines *in vivo* [10]. In future studies, we will examine the autocrine/paracrine contribution of these cytokines to CRP-induced superoxide and tissue factor activity *in vivo*.

Immunocytochemical detection of Fc gamma (F $\gamma$ ) receptors in human atherosclerotic lesions has been demonstrated [37]. The activation of F $\gamma$ Rs generates oxygen radicals by phagocytes and immune cells. Ryu et al. [6] have demonstrated that F $\gamma$ RIIa exclusively mediates CRP-induced intracellular ROS generation by human vascular smooth muscle cells [6]. Also, they showed that CRP-induced F $\gamma$ RIIa activation modulates activation of AP-1 and NF $\kappa$ b and p22phox and inhibition of p22phox abrogates ROS in vascular smooth muscle cells *in vitro*. We have previously shown that blocking of CD32/CD64 in endothelial cells abrogate effects of CRP [5,10,11,24,28]. Also, recently we showed that CRP induces superoxide anion release in endothelial cells and promotes eNOS uncoupling, this is reversed by inhibition of CD32 and CD64 [5]. In addition, in human monocytes and U937 histiocytes, CRP has been shown to induce CCR2 expression via CD64 [26] and matrix met-alloproteinase (MMP)-1 expression via CD32, respectively. In neutrophils, CRP-mediated effects have been reported to be via CD16. Furthermore, the Fay group recently reported CRP-mediated TF release appears to be via CD16 in vascular smooth muscle cells *in vitro* [12]. In this paper, we report that CRP-mediated superoxide anion release and tissue factor activity are abrogated by inhibition of CD32 and CD64, with no effect of CD16 inhibition in rat pouch macrophages *in vivo*.

To conclude, in the present study we make the novel observation that CRP induces superoxide anion release and tissue factor activity *in vivo* using the rat sterile air pouch model and that superoxide release appears to precede tissue factor release. These data provide further evidence for the role of CRP in promoting atherothrombosis.

## Acknowledgements

This work was supported by National Institutes of Health Grant RO1 HL074360 as well as NIHK24 AT00596 to I. Jialal.


## References

1. Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. *Nutr Rev* 2007;65:S140–6. [PubMed: 18240538]
2. Stocker R, Keaney JF Jr. New insights on oxidative stress in the artery wall. *J Thromb Haemost* 2005;3:1825–34. [PubMed: 16102049]
3. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. *Circulation* 2006;113:2135–50. [PubMed: 16671184]
4. Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. *Circulation* 2003;108:1676–8. [PubMed: 14504187]

5. Singh U, Devaraj S, Vasquez-Vivar J, Jialal I. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. *J Mol Cell Cardiol* 2007;43:780–91. [PubMed: 17942113]
6. Ryu J, Lee CW, Shin JA, et al. FcγRIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. *Cardiovasc Res* 2007;75:555–65. [PubMed: 17531211]
7. Qamirani E, Ren Y, Kuo L, Hein TW. CRP inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. *Arterioscler Thromb Vasc Biol* 2005;25:995–1001. [PubMed: 15718491]
8. Zeller JM, Sullivan BL. C-reactive protein selectively enhances the intracellular generation of reactive oxygen products by IgG-stimulated monocytes and neutrophils. *J Leukoc Biol* 1992;52:449–55. [PubMed: 1328445]
9. Kobayashi S, Inoue N, Ohashi Y, et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. *Arterioscler Thromb Vasc Biol* 2003;23:1398–404. [PubMed: 12805076]
10. Singh U, Dasu MR, Yancey PG, et al. Human C-reactive protein promotes oxidized low-density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. *J Lipid Res* 2008;49:1015–23. [PubMed: 18245817]
11. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. *Circulation* 2003;107:398–404. [PubMed: 12551862]
12. Wu J, Stevenson MJ, Brown JM, et al. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and *in vivo* significance. *Arterioscler Thromb Vasc Biol* 2008;28:698–704. [PubMed: 18276908]
13. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. *Circulation* 2003;108:512–5. [PubMed: 12874178]
14. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. *J Exp Med* 1999;190:1733–40. [PubMed: 10601349]
15. Gill R, Kemp JA, Sabin C, Pepys MB. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. *J Cereb Blood Flow Metab* 2004;24:1214–8. [PubMed: 15545914]
16. Ikeda U, Maeda Y, Yamamoto K, Shimada K. C-reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. *Cardiovasc Res* 2002;56:86–92. [PubMed: 12237169]
17. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. *Cardiovasc Res* 2003;58:186–95. [PubMed: 12667961]
18. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. *Nature* 2006;440:1217–21. [PubMed: 16642000]
19. Du Clos TW, Zlock LT, Marnell L. Definition of a C-reactive protein binding determinant on histones. *J Biol Chem* 1991;266:2167–71. [PubMed: 1989977]
20. Dasu MR, Devaraj S, Du Clos TW, Jialal I. The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. *J Lipid Res* 2007;48:509–12. [PubMed: 17158793]
21. Davies DE, Stevens AJ, Houston JB. Use of the rat air pouch model of inflammation to evaluate regional drug delivery. *Agents Actions*. 1992Spec No.: C109–11
22. Pendurthi UR, Rao LV. Effect of wine phenolics and stilbene analogues on tissue factor expression in endothelial cells. *Thromb Res* 2002;106:205–11. [PubMed: 12297127]
23. Venugopal SK, Devaraj S, Yang T, Jialal I. Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-α. *Diabetes* 2002;51:3049–54. [PubMed: 12351446]
24. Devaraj S, Davis B, Simon SI, Jialal I. CRP promotes monocyte–endothelial cell adhesion via Fcγ receptors in human aortic endothelial cells under static and shear flow conditions. *Am J Physiol Heart Circ Physiol* 2006;291:H1170–6. [PubMed: 16603696]


25. Williams TN, Zhang CX, Game BA, He L, Huang Y. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. *Arterioscler Thromb Vasc Biol* 2004;24:61–6. [PubMed: 14592848]
26. Han KH, Hong KH, Park JH, et al. CRP promotes MCP-1 mediated chemotaxis through upregulating CCR2 expression in human monocytes. *Circulation* 2004;109:2566–71. [PubMed: 15136507]
27. Singh U, Devaraj S, Dasu MR, et al. C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. *Arterioscler Thromb Vasc Biol* 2006;26:2469–75. [PubMed: 16917108]
28. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. *Arterioscler Thromb Vasc Biol* 2005;25:1359–63. [PubMed: 15860734]
29. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or atorvastatin evaluation and infection therapy —thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med* 2005;352:20–8. [PubMed: 15635109]
30. Niccoli G, Biasucci LM, Biscione C, et al. Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina. *Atherosclerosis* 2008;196:779–85. [PubMed: 17306806]
31. Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Di Biase M. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. *Int J Cardiol* 2006;109:248–56. [PubMed: 16055214]
32. Prasad K. C-reactive protein increases oxygen radical generation by neutrophils. *J Cardiovasc Pharmacol Ther* 2004;9:203–9. [PubMed: 15378141]
33. Trachtman H, Futterweit S, Arzberger C, et al. Nitric oxide and super-oxide in rat mesangial cells: modulation by C-reactive protein. *Pediatr Nephrol* 2006;21:619–26. [PubMed: 16565872]
34. Cermak J, Key NS, Bach RR, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. *Blood* 1993;82:513–20. [PubMed: 8329706]
35. Paffen E, Vos HL, Bertina RM. C-reactive protein does not directly induce tissue factor in human monocytes. *Arterioscler Thromb Vasc Biol* 2004;24:975–81. [PubMed: 15044210]
36. Cirillo P, Golino P, Calabrò P, et al. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. *Cardiovasc Res* 2005;68:47–55. [PubMed: 16023093]
37. Ratcliffe NR, Kennedy SM, Morganelli PM. Immunocytochemical detection of Fc  $\gamma$ R in human atherosclerotic lesions. *Immunol Lett* 2001;77:169–74. [PubMed: 11410250]






**Fig. 1.**

(a) Effect of CRP on superoxide anion release in rat macrophages: HCRP/HuSA (20 mg/kg bw for 3 days,  $n = 5$  in each group) was injected in the peritoneal cavity of the rats. The rats were sacrificed on the 4th day and peritoneal macrophages were isolated. Superoxide anion release was assessed by DHE fluorescence (Panel 1) and ferricytochrome C reduction (Panel 2) as depicted in Section 2. Panel 3 is a representative picture of macrophages loaded with DHE. The results are mean  $\pm$  S.D. of five different experiments and are expressed as per mg cell protein.  $*p < 0.01$  compared to HuSA. (b) Effect of CRP on tissue factor activity in rat macrophages: HCRP/HuSA (20 mg/kg bw for 3 days,  $n = 5$  in each group) was injected in the peritoneal cavity of the rats. The rats were sacrificed on the 4th day and peritoneal macrophages were isolated. Tissue factor activity was assessed as described in Section 2.  $*p < 0.05$  compared to HuSA.




**Fig. 2.**

(a) Effect of inhibitors to PKC (10 µM calphostin C), NADPH oxidase (100 µg/mL apocynin), on superoxide anion release and (b) effect of inhibitors to PKC (10 µM calphostin C), ROS scavengers (NAC, 10 µg/mL; DPI, 10 µM; apocynin, 100 µg/mL), on tissue factor activity in pouch macrophages. Inhibitors were injected into sterile air pouches of Wistar rats ( $n = 3$  in each group) at least 2 h prior to administration of HCRP (25 µg/mL) or HuSA and superoxide and tissue factor were assessed as described in Section 2. The results are mean  $\pm$  S.D. \* $p < 0.05$  compared to HuSA and # $p < 0.05$  compared to HCRP.



**Fig. 3.** Effect of inhibitors to MAPK and NFκB on (a) superoxide anion release and (b) tissue factor activity in pouch macrophages. Inhibitors to p38MAPK, ERK, JNK or NFκB were injected into sterile air pouches of Wistar rats ( $n = 3$  in each group) at least 2 h prior to administration of HCRP (25 μg/mL) or HuSA and superoxide and tissue factor were assessed as described in Section 2. The results are mean  $\pm$  S.D. <sup>#</sup> $p < 0.05$  compared to CRP.



**Fig. 4.** Effect of pretreatment with antibodies (10  $\mu\text{g}/\text{mL}$  each separately) to Fc gamma receptors; CD32, CD64, CD16 on (a) superoxide anion release and (b) tissue factor activity in pouch macrophages as described in Section 2. Antibodies to CD16, CD32 and CD64 were injected into sterile air pouches of Wistar rats ( $n = 3$  in each group) at least 2 h prior to administration of HCRP (25  $\mu\text{g}/\text{mL}$ ) or HuSA and superoxide and tissue factor were assessed as described in Section 2. The results are mean  $\pm$  S.D. <sup>#</sup> $p < 0.05$  compared to CRP.